It is produced by osteoblasts, dendritic cells, B cells, etc., and can compete with RANK to bind RANKL and inhibit bone resorption.[46,57] At present, long-term use of anti-osteoporosis drugs can cause some adverse reactions.[8] Targeted treatment of OP through the RANKL/RANK/OPG pathway and downstream cascade transduction signaling pathway is a hot spot of current research. This evidence concerns the gene TNFRSF11A and osteoporosis.